Drugs / AP-SA02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05184764 | Apr 2022 → Nov 2024 | staphylococcus aureus infection | Armata Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP-SA02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05184764 ↗ |
| Modality | Other / unclassified | “Anti-staphylococcal bacteriophage” NCT05184764 ↗ |
| Route | Intravenous | “Bacteriophage administered via intravenous bolus infusion” NCT05184764 ↗ |